PL1996626T3 - Anty-idiotypowe przeciwciało, które zobojętnia hamującą aktywność przeciwciała hamującego skierowanego przeciwko domenie C1 czynnika VIII - Google Patents

Anty-idiotypowe przeciwciało, które zobojętnia hamującą aktywność przeciwciała hamującego skierowanego przeciwko domenie C1 czynnika VIII

Info

Publication number
PL1996626T3
PL1996626T3 PL07731046T PL07731046T PL1996626T3 PL 1996626 T3 PL1996626 T3 PL 1996626T3 PL 07731046 T PL07731046 T PL 07731046T PL 07731046 T PL07731046 T PL 07731046T PL 1996626 T3 PL1996626 T3 PL 1996626T3
Authority
PL
Poland
Prior art keywords
tyr
ser
thr
asn
ala
Prior art date
Application number
PL07731046T
Other languages
English (en)
Inventor
Jean-Guy Gilles
Marc G Jacquemin
Jean-Marie Saint-Remy
Christian Behrens
Original Assignee
Lfb Biotechnologies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lfb Biotechnologies filed Critical Lfb Biotechnologies
Publication of PL1996626T3 publication Critical patent/PL1996626T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL07731046T 2006-02-24 2007-02-26 Anty-idiotypowe przeciwciało, które zobojętnia hamującą aktywność przeciwciała hamującego skierowanego przeciwko domenie C1 czynnika VIII PL1996626T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0601633A FR2897868B1 (fr) 2006-02-24 2006-02-24 Anticorps anti-idiotypiques neutralisant l'activite inhibitrice d'un anticorps inhibiteur dirige contre le domaine c1 du facteur viii.
EP07731046A EP1996626B1 (fr) 2006-02-24 2007-02-26 Anticorps anti-idiotypiques neutralisant l'activite inhibitrice d'un anticorps inhibiteur dirige contre le domaine c1 du facteur viii
PCT/FR2007/000342 WO2007096536A1 (fr) 2006-02-24 2007-02-26 Anticorps anti-idiotypiques neutralisant l'activite inhibitrice d'un anticorps inhibiteur dirige contre le domaine c1 du facteur viii

Publications (1)

Publication Number Publication Date
PL1996626T3 true PL1996626T3 (pl) 2012-04-30

Family

ID=37106244

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07731046T PL1996626T3 (pl) 2006-02-24 2007-02-26 Anty-idiotypowe przeciwciało, które zobojętnia hamującą aktywność przeciwciała hamującego skierowanego przeciwko domenie C1 czynnika VIII

Country Status (15)

Country Link
US (2) US20080160015A1 (pl)
EP (3) EP2447284A1 (pl)
JP (1) JP2009528285A (pl)
KR (1) KR20080106289A (pl)
CN (1) CN101522718A (pl)
AT (1) ATE530579T1 (pl)
AU (1) AU2007217218A1 (pl)
BR (1) BRPI0707031A2 (pl)
CA (1) CA2643565A1 (pl)
DK (1) DK1996626T3 (pl)
ES (1) ES2376489T3 (pl)
FR (1) FR2897868B1 (pl)
IL (1) IL193212A0 (pl)
PL (1) PL1996626T3 (pl)
WO (1) WO2007096536A1 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2889534B1 (fr) * 2005-08-04 2012-11-02 Lab Francais Du Fractionnement Anticorps anti-idiotypique neutralisant l'activite inhibitrice d'un anticorps inhibiteur du facteur viii
JP2010536363A (ja) * 2007-08-23 2010-12-02 エルエフビー バイオテクノロジース ファクターｖｉｉｉのｃ１ドメインに対する阻害抗体の阻害活性を中性化する抗イデオタイプ抗体
FR2933496B1 (fr) * 2008-07-02 2012-10-05 Lfb Biotechnologies Procede de mesure du taux de facteur vii active dans un echantillon
CA2771999A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor vii compositions and methods of making and using same
FR2969761A1 (fr) * 2010-12-22 2012-06-29 Lfb Biotechnologies Procede de dosage d'anticorps diriges contre le facteur viii
JP6256882B2 (ja) 2012-02-15 2018-01-10 アムニクス オペレーティング インコーポレイテッド 第ｖｉｉｉ因子組成物、ならびに組成物の作製方法および用途
EP2822577B1 (en) 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
EP3722320A3 (en) 2012-10-25 2020-12-30 Bioverativ USA Inc. Anti-complement c1s antibodies and uses thereof
DK2914291T3 (da) 2012-11-02 2022-05-16 Bioverativ Usa Inc Anti-komplement-c1s-antistoffer og anvendelser deraf
TW202003554A (zh) 2013-08-14 2020-01-16 美商百歐維拉提夫治療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
CA2981321A1 (en) 2015-04-06 2016-10-13 True North Therapeutics, Inc. Humanized anti-c1s antibodies and methods of use thereof
EA201890423A1 (ru) 2015-08-03 2018-07-31 Биовератив Терапьютикс Инк. Слитые белки фактора ix, способы их получения и применения
CN110300520B (zh) * 2016-10-12 2022-10-04 美国比奥维拉迪维股份有限公司 抗C1s抗体及其使用方法
MX2019006444A (es) 2016-12-02 2019-10-30 Bioverativ Therapeutics Inc Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
PL3793588T3 (pl) 2018-05-18 2025-09-01 Bioverativ Therapeutics Inc. Sposoby leczenia hemofilii a

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR508320A (fr) 1920-01-12 1920-10-07 Deynoux Freres Fermoir pour sacs et objets analogues
WO2001004269A1 (en) * 1999-07-14 2001-01-18 D. Collen Research Foundation Vzw Ligands for use in therapeutic compositions for the treatment of hemostasis disorders
EP1388544A1 (en) * 2002-07-31 2004-02-11 D. Collen Research Foundation vzw Anti-idiotypic antibodies against factor VIII inhibitor and uses thereof
CA2535489C (en) * 2003-08-14 2014-09-30 D. Collen Research Foundation Vzw Antibodies against factor viii with modified glycosylation in the variable region
FR2889534B1 (fr) 2005-08-04 2012-11-02 Lab Francais Du Fractionnement Anticorps anti-idiotypique neutralisant l'activite inhibitrice d'un anticorps inhibiteur du facteur viii

Also Published As

Publication number Publication date
KR20080106289A (ko) 2008-12-04
JP2009528285A (ja) 2009-08-06
EP1996626B1 (fr) 2011-10-26
ES2376489T3 (es) 2012-03-14
CN101522718A (zh) 2009-09-02
US8110190B2 (en) 2012-02-07
EP2100903A2 (fr) 2009-09-16
EP2100903A3 (fr) 2010-01-20
US20080160015A1 (en) 2008-07-03
FR2897868A1 (fr) 2007-08-31
AU2007217218A1 (en) 2007-08-30
BRPI0707031A2 (pt) 2011-04-12
DK1996626T3 (da) 2012-02-13
FR2897868B1 (fr) 2012-08-31
EP2447284A1 (fr) 2012-05-02
CA2643565A1 (en) 2007-08-30
IL193212A0 (en) 2009-02-11
US20090263380A1 (en) 2009-10-22
ATE530579T1 (de) 2011-11-15
WO2007096536A1 (fr) 2007-08-30
EP1996626A1 (fr) 2008-12-03

Similar Documents

Publication Publication Date Title
IL193212A0 (en) Anti-idiotypic antibody which neutralizes the inhibitory activity of an inhibitory antibody directed against the c1 domain of factor viii
LT2005099A (en) Antibodies directed to monoclonal chemo-atractant protein-1 (mcp-1) and uses thereof
TW200716182A (en) Antibodies directed to CD20 and uses thereof
TW200637873A (en) Antibodies against interleukin-1 beta
TW200716677A (en) Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
MX2007007484A (es) Anticuerpos dirigidos a angiopoyetina 2 y usos de los mismos.
NO20063569L (no) M-CSF-spesifikt monoklonalt antistoff og anvendelse derav
SG155883A1 (en) Anti-cd3 antibodies and methods of use thereof
WO2008112004A3 (en) ANTIBODIES DIRECTED TO αVβ6 AND USES THEREOF
EP1578799B8 (en) Antibodies directed to tumor necrosis factor and uses thereof
SG151284A1 (en) Antibodies against ccr5 and uses thereof
MXPA05005925A (es) Anticuerpos dirigidos a la fosfolipasa a2 y sus usos.
WO2007120693A3 (en) Targeted binding agents directed to upar and uses thereof
WO2006052591A3 (en) Anti-properdin antibodies, and methods for making and using same
BE2017C068I2 (pl)
NZ621103A (en) Humanized anti-factor d antibodies and uses thereof
WO2006055638A3 (en) Fully human monoclonal antibodies to il-13
WO2003057857A3 (en) Antibodies directed to pdgfd and uses thereof
NZ599683A (en) Anti-ilt7 antibody
WO2006104978A3 (en) Antibodies against the tenascin major antigens
NZ594275A (en) B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
NZ581835A (en) Monoclonal anti beta amyloid antibody
NZ591636A (en) Sclerostin binding agents
RU2011140509A (ru) Гетеродимерные полипептиды il-17a/f и возможности их лечебного применения
WO2008133641A3 (en) Antibodies directed to gpnmb and uses thereof